Ardent Health (NYSE:ARDT) Given New $13.50 Price Target at UBS Group

Ardent Health (NYSE:ARDT) had its price objective lifted by UBS Group from $13.00 to $13.50 in a research report sent to investors on Thursday morning,Benzinga reports. UBS Group currently has a buy rating on the stock.

Other analysts have also issued research reports about the stock. JPMorgan Chase & Co. dropped their target price on shares of Ardent Health from $12.00 to $11.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 20th. Zacks Research upgraded shares of Ardent Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, March 25th. Royal Bank Of Canada dropped their target price on shares of Ardent Health from $14.00 to $13.00 and set an “outperform” rating for the company in a report on Monday, March 9th. Finally, Leerink Partners reduced their target price on shares of Ardent Health from $16.00 to $15.00 and set an “outperform” rating for the company in a research report on Friday, March 6th. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $14.21.

Ardent Health Stock Up 5.4%

Shares of NYSE ARDT opened at $9.88 on Thursday. The company’s 50-day simple moving average is $9.26 and its 200-day simple moving average is $9.75. Ardent Health has a 52-week low of $8.07 and a 52-week high of $15.48. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of 10.39 and a beta of 0.93. The company has a quick ratio of 1.85, a current ratio of 1.97 and a debt-to-equity ratio of 0.64.

Ardent Health (NYSE:ARDT) last announced its earnings results on Tuesday, May 5th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.10. Ardent Health had a net margin of 2.09% and a return on equity of 14.01%. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS. Equities analysts predict that Ardent Health will post 1.11 EPS for the current fiscal year.

Hedge Funds Weigh In On Ardent Health

A number of institutional investors and hedge funds have recently bought and sold shares of ARDT. Caitong International Asset Management Co. Ltd boosted its position in Ardent Health by 1,177.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,862 shares of the company’s stock worth $25,000 after acquiring an additional 2,638 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Ardent Health during the third quarter worth about $61,000. Monetary Solutions Ltd acquired a new position in Ardent Health during the fourth quarter worth about $79,000. KLP Kapitalforvaltning AS acquired a new position in Ardent Health during the third quarter worth about $80,000. Finally, New York State Common Retirement Fund increased its position in Ardent Health by 121.4% during the second quarter. New York State Common Retirement Fund now owns 6,200 shares of the company’s stock worth $85,000 after purchasing an additional 3,400 shares during the last quarter.

About Ardent Health

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.